AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04204551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high-intensity interval training (HIIT)
Description: Two 12-week HIIT cycles will be divided with 3 months of break. Each HIIT cycle will consist of three 1-hour training sessions weekly. Each 1-hour training session will consist of 10-minutes warm-up (at slow voluntary speed), 40-minutes of interval exercise and 10-minutes cool-down phase. The interval exercise part will consist of 10 sets of 4 minutes interval including 2-minutes cycling at ≥ 60 \[rpm\], but preferably at 80-90 \[rpm\] (fast phase of interval) and 2-minutes cycling at ≤ 60 \[rpm\] (slow phase of interval). The training will be performed on a stationary cycle ergometer (MONARK, Ergomedic 874E, Sweden). The heart rate (HR, \[bpm\]) will be measured by Polar system (Polar, Finland). The patients will pedal on the cycloergometer at 60%-80% of their individualized HRmax.
Study NCT04204551 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physical therapy
Description: Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
Study NCT01251783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Metlos + lactobacillus GG
Description: A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
Study NCT01251783 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus GG
Description: An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
Study NCT04388306 — intervention group
Intervention type: OTHER
Intervention: Shoulder Performance Test- Functional Impairment Test-Head and Neck, Shoulder, Arm (FIT-HaNSA)
Description: Participants were evaluated with all tests, respectively. To eliminate the fatigue factor, 5 minutes breaks were given after each test.
Study NCT04431115 — intervention group
Intervention type: OTHER
Intervention: Interviews
Description: Interviews for stakeholders
Study NCT02713568 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound examination
Description: Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.~Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.~For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin.
Study NCT02713568 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic resonance examination
Description: MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.~Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031\*Fetal Body Volume = MR imaging weight (g) developed by Baker.~General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.~For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99.
Study NCT01990287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCS and PNfS
Description: Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
Study NCT01990287 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCS Alone
Description: Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
Study NCT04001855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dilute vinegar (acetic acid)
Description: Dilute vinegar baths or gauze soaks
Study NCT04001855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dilute bleach
Description: Dilute bleach baths or gauze soaks
Study NCT02676687 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: total resection
Description: Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
Study NCT02676687 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: supratotal resection
Description: Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
Study NCT01656434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
Study NCT01656434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NETA-EE
Description: NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
Study NCT01656434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: tablet
Study NCT01656434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ethinylestradiol (EE)
Description: EE 10 μg tablet
Study NCT01656434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate
Description: ferrous fumarate 75 mg tablet
Study NCT03213366 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-PrEP- Peer-Led Intervention about PrEP
Description: Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
Study NCT03213366 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BxNow - General Health Campaign
Description: BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
Study NCT02112500 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
Study NCT00615615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: * high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg~* low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less
Study NCT00615615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy
Study NCT01710488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 1 tablet 500 mg once a day
Description: Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.
Study NCT01710488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 1 tablet 600 mg once a day
Description: Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:~Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food.
Study NCT00876083 — intervention group
Intervention type: DRUG
Intervention: Ultravist (Iopromide, BAY86-4877)
Description: Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
Study NCT00151671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Impact®
Description: Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
Study NCT00151671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
Study NCT04128540 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fentanyl
Description: fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
Study NCT04128540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: fentanyl infusion at a dose of (1 μg/kg/hour) after induction of anesthesia and to be continued all through the whole operation.rescue analgesia by a bolus of (Fentanyl 1mcg/kg) will be given to the patients in either group, if either systolic blood pressure or heart rate increased more than 20% of the baseline readings.
Study NCT04128540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: ultrasound guided erector spinae plane block by injecting 0.4ml/kg (1:1 solution of bupivacaine 0.25% and lidocaine 1%). This will be performed at the same side of the planned thoracotomy under strict aseptic precautions.A high frequency 12 MHz linear ultrasound transducer will be placed in a longitudinal orientation 3 cm lateral to the T3 spinous process corresponding to the T2 transverse process.~Three muscles; trapezius, rhomboids major, and erector spinae will be identified superior to the hyperechoic transverse process.~Using in-plane approach a 25 G needle will be inserted in caudal-cephalic direction, until the tip is deep to erector spinae muscle.~Correct needle tip location will be confirmed by injecting 3 mL of normal saline and visualizing the linear LA spread in the fascial plane between the erector spinae muscle and the transverse process..
Study NCT03847610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenoxymethyl Penicillin
Description: Phenoxymethylpenicillin tablets, 500mg every six hours for six doses, starting the day before study
Study NCT03847610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microneedle array
Description: The microneedle biosensor will be sited peripherally (on the non-dominant arm) for the duration of the study. It will then be removed.
Study NCT01235962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib monohydrochloride salt was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
Study NCT01235962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo matching pazopanib was supplied as aqueous, film-coated tablets containing 200 mg of the free base. The 200 mg tablets were oval-shaped and white in color.
Study NCT01235962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
Study NCT01235962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
Study NCT00087646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg po daily for 72 weeks
Study NCT00087646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000/1200mg po daily for 48 weeks
Study NCT00087646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: 1000/1200mg po daily for 48 weeks
Study NCT00087646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
Study NCT00087646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
Study NCT00087646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 72 weeks
Study NCT00087646 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 48 weeks
Study NCT05401305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccine for the prevention of infections caused by Haemophilus influenza type b
Description: The vaccine is administered into the region of the deltoid muscle
Study NCT05401305 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is administered into the region of the deltoid muscle
Study NCT03504592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Completion of Glucose logs
Description: Glucose logs will be assessed by provider for completeness and accuracy
Study NCT04204551 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physical therapy
Description: Conventional physical therapy as prescribed and provided by the National Health Fund of Poland, which includes activities for improving motor control, but without any kind of moderate or high intensity aerobic interval or continuous physical training (example: cycle ergometer, treadmill, or Nordic walking training)
Study NCT00505076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0777
Description: MK-0777 GEM, 8 mg BID
Study NCT03504592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Completion of Glucose logs
Description: Glucose logs will be assessed by provider for completeness and accuracy
Study NCT03462056 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cystic Fibrosis Ready to Use Supplemental Food
Description: Specially formulated for use by children with Cystic Fibrosis
Study NCT00505076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0777
Description: MK-0777 GEM, 3 mg BID
Study NCT00505076 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tablets placebo BID
Study NCT02697149 — intervention group
Intervention type: RADIATION
Intervention: nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography
Description: All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
Study NCT02697149 — intervention group
Intervention type: RADIATION
Intervention: standard endoscopic retrograde cholangiopancreatography
Description: Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
Study NCT02291016 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol
Description: Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
Study NCT02291016 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
Study NCT03298971 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
Study NCT04093024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Capsule
Study NCT04093024 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule
Study NCT01499706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 1-session of telephone-administered motivational interviewing
Description: Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
Study NCT01499706 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4-session telephone-administered motivational interviewing
Description: Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
Study NCT03287518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: WAK2017
Description: WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
Study NCT03287518 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
Study NCT03138980 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BodiMojo Buddy for IBS
Description: Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature.
Study NCT01485692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol+promethazine
Description: haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
Study NCT01485692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: haloperidol + midazolam
Description: haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
Study NCT01485692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
Study NCT01485692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
Study NCT00687284 — intervention group
Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
Study NCT01409603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darexaban
Description: oral
Study NCT01409603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: oral
Study NCT00271284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glulisine / insulin glargine
Description: insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
Study NCT00271284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glulisin / insulin detemir
Description: insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00